EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Self-reported exercise and bone mineral density in prostate cancer patients receiving androgen deprivation therapy



Self-reported exercise and bone mineral density in prostate cancer patients receiving androgen deprivation therapy



Journal of the American Association of Nurse Practitioners 26(1): 40-48



Men with prostate cancer receiving androgen deprivation therapy (ADT) are at increased risk for decreased bone mineral density (BMD). This study evaluates the relationship between self-reported daily activity, endurance and resistance exercise, and BMD measured by dual-energy x-ray absorptiometry (DEXA) in prostate cancer patients receiving ADT. We recruited 96 men treated with ADT for ≥9 months from urology and cancer practices. The Canadian Fitness Survey assessed daily activity and exercise. Data on demographic and lifestyle characteristics and calcium and vitamin D supplementation were collected. Blood was collected for analysis of 25-OH vitamin D. A DEXA scan was performed. A positive association between endurance exercise and DEXA T-scores of the hip was shown. Regression analysis showed endurance exercise of medium to heavy intensity (measured as energy expenditure in MET-hours/week) was associated with T-scores of the hip (β = 0.048; 95% CI 0.003, 0.112; p = .040) but not with spinal T-scores after controlling for age, body mass index, and alcohol use. Findings are cross-sectional, but if confirmed in prospective studies suggest that increased endurance exercise is a practical measure nurse practitioners can institute to prevent low bone density in the hip of men treated with ADT.

(PDF emailed within 0-6 h: $19.90)

Accession: 055706025

Download citation: RISBibTeXText

PMID: 24170604

DOI: 10.1002/2327-6924.12066



Related references

Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab. Anticancer Research 37(7): 3667-3671, 2017

Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. Clinical Genitourinary Cancer: -, 2018

Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Journal of Urology 182(6): 2670-2675, 2009

Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. Journal of Urology 187(3): 889-893, 2012

Toremifene citrate increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 24(18_suppl): 4553-4553, 2016

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. International Journal of Radiation Oncology, Biology, Physics 85(5): 1239-1245, 2013

Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. Bju International 104(6): 800-805, 2009

Androgen deprivation therapy in patients with prostate cancer and changes in bone mineral density. Journal of Bone & Mineral Research 16(Suppl 1): S243, September, 2001

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. Journal of Urology 179(1): 152-155, 2007

Bone mineral density changes in men receiving androgen deprivation for advanced prostate cancer. Journal of Urology 163(4 Suppl ): 262, April, 2000

Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian Journal of Andrology 6(1): 75-77, 2004

Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy. Collegium Antropologicum 29(2): 589-591, 2006

Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocrine-Related Cancer 15(4): 943-952, 2008

Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer. Journal of General Internal Medicine 28(11): 1440-1446, 2014

Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer. In Vivo 32(2): 409-412, 2018